U.S. Markets closed

Wired News – Alexion Pharma Announced Acceptance of Offer by Wilson Therapeutics

Stock Monitor: CEL-SCI Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) ("Alexion"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALXN as the Company's latest news hit the wire. On May 25, 2018, the Company announced that its offer, through a wholly owned subsidiary, for the shares in Sweden-based Wilson Therapeutics has been accepted by shareholders, representing 97.7% of the total number of shares and votes in Wilson Therapeutics. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for CEL-SCI Corporation (NYSE AMER: CVM), which also belongs to the Healthcare sector as the Company Alexion Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CVM

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Alexion Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ALXN

Alexion Extended Acceptance Period until June 08, 2018

The acquisition has been approved by relevant regulatory authorities. The offer has been declared unconditional and settlement of the tendered shares will occur on May 30, 2018. In order to give Wilson Therapeutics' shareholders additional time to accept the offer, Alexion has extended the acceptance period until June 08, 2018. Settlement for shares tendered during this extended acceptance period is expected on June 15, 2018.

Alexion plans to initiate compulsory redemption proceedings regarding the remaining shares in Wilson Therapeutics as well as to promote a delisting of the shares from Nasdaq Stockholm.

Acquisition of Wilson Therapeutics - Key First Step in Rebuilding Alexion's Pipeline

Commenting on the announcement, Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion, stated that the acquisition of Wilson Therapeutics is a key first step in rebuilding the Company's pipeline.

Ludwig added that Alexion looks forward to using its significant experience in rare metabolic and neurological diseases to improve treatment for patients with Wilson disease through the development of WTX101, which has the potential to be the first new treatment in more than 20 years and become the new standard of care for Wilson disease.

Alexion Initiated the Offer in April 2018

On April 11, 2018, Alexion made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares by way of a tender offer, through a wholly-owned subsidiary. Alexion offered SEK 232 in cash for each outstanding share of Wilson Therapeutics. The total equity value of the transaction amounted to SEK 7,100 million (approximately $855 million). Alexion obtained support agreements for the takeover from investors holding a total of 73.4% of Wilson Therapeutics' outstanding shares. The acquisition required approval of relevant regulatory authorities. Alexion will finance the acquisition through cash on hand.

About WTX101

WTX101 is a first-in-class oral copper-binding agent with a unique mechanism of action and ability to access and bind copper from serum and promote its removal from the liver. A Phase-2 study evaluating the efficacy and safety of WTX101 in Wilson Disease patients was successfully completed in 2016, and Phase-3 is in development. WTX101 has received Fast Track designation in the US and Orphan Drug Designation for the treatment of Wilson disease in the US and the EU.

About Wilson Disease

Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Wilson disease is often fatal if not recognized and treated when symptomatic. The average age of diagnosis is 15-20 years, with the majority of patients presenting between the ages of 10 and 30.

About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company that develops novel therapies for patients with rare diseases. The Company's lead product, WTX101, is in development as a novel treatment for Wilson Disease. The Company was established in 2012 and is based in Stockholm, Sweden.

About Alexion Pharmaceuticals, Inc.

Founded in 1992 and headquartered in New Haven, Connecticut, Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases.

Stock Performance Snapshot

May 29, 2018 - At Tuesday's closing bell, Alexion Pharma's stock fell 1.71%, ending the trading session at $115.73.

Volume traded for the day: 1.34 million shares.

Stock performance in the previous six-month period – up 6.56%; and past twelve-month period – up 18.45%

After yesterday's close, Alexion Pharma's market cap was at $25.70 billion.

Price to Earnings (P/E) ratio was at 42.77.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst. For further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors